RECRUITINGOBSERVATIONAL

To Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC Surveillance.

Addition of GAAD Score to Imaging Surveillance for Early Identification of Liver Cancer.

About This Trial

The goal of this prospective observational study is to test the impact of addition of the GAAD score to imaging in patients with chronic liver disease eligible for HCC surveillance. The main questions it aims to answer are: * Diagnostic accuracy of the GAAD score (cut-off 2.57 (3)) for detection of HCC (overall and by BCLC stage), expressed using sensitivity, specificity, negative predictive value and positive predictive value. * Change in GAAD score over time, and proportion of patients with a GAAD score above the cut-off over time in relation to potential confounding factors (e.g. age, bilirubin levels, presence of HCC). 1000 participants with chronic liver disease eligible for HCC surveillance will be enrolled. Data will be collected for 3 consecutive years after enrollment. As per clinical practice, patients will undergo standard bi-annual HCC surveillance comprising liver imaging with ultrasound (or CT or MRI based on previous investigations) and GAAD score assessment based on blood samples.

Who May Be Eligible (Plain English)

Who May Qualify: - All patients with cirrhosis - Non-cirrhotic chronic hepatitis B patients meeting any of the following criteria: positive family history for HCC, intermediate-high aMAP and/or (m)PAGE-B score (if non-Caucasian) - Non-cirrhotic chronic hepatitis C patients (with or without SVR) with a history of F3 fibrosis (based on histology or liver stiffness assessment) - Non-cirrhotic NASH patients with a history of F3 fibrosis (based on histology or liver stiffness assessment) Who Should NOT Join This Trial: - Diagnosis with any other cancer other than non-melanoma skin cancer - History of HCC - Women who are pregnant or lactating - Patient with glomerular filtration rate \<45 ml /min/1.73 m2 - Unwillingness or inability to undergo both CT and MRI imaging - Life expectancy \<2 years - Use of vitamin K antagonists Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * All patients with cirrhosis * Non-cirrhotic chronic hepatitis B patients meeting any of the following criteria: positive family history for HCC, intermediate-high aMAP and/or (m)PAGE-B score (if non-Caucasian) * Non-cirrhotic chronic hepatitis C patients (with or without SVR) with a history of F3 fibrosis (based on histology or liver stiffness assessment) * Non-cirrhotic NASH patients with a history of F3 fibrosis (based on histology or liver stiffness assessment) Exclusion Criteria: * Diagnosis with any other cancer other than non-melanoma skin cancer * History of HCC * Women who are pregnant or lactating * Patient with glomerular filtration rate \<45 ml /min/1.73 m2 * Unwillingness or inability to undergo both CT and MRI imaging * Life expectancy \<2 years * Use of vitamin K antagonists

Treatments Being Tested

DIAGNOSTIC_TEST

GAAD score

In order to calculate the GAAD score an in-vitro diagnostic is used. The Elecsys GAAD assay by Roche Diagnostics is used to assess the GAAD score using on blood samples collected from patients during regular outpatient clinic visits. The Elecsys GAAD test combines the results of the Elecsys PIVKA-II and Elecsys AFP assays with gender and age (the GAAD score is calculated with PIVKA-II, AFP, gender and age).

Locations (1)

Erasmus MC

Rotterdam, CA, Netherlands